MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597965 | Name: RC 121

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RC 121 is a highly potent somatostatin (SRIF) analog.

Chemical Structure

RC 121
RC 121
CAS#99660-13-6

Theoretical Analysis

MedKoo Cat#: 597965

Name: RC 121

CAS#: 99660-13-6

Chemical Formula: C50H67N11O10S2

Exact Mass: 1045.4514

Molecular Weight: 1046.27

Elemental Analysis: C, 57.40; H, 6.45; N, 14.73; O, 15.29; S, 6.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RC 121; RC-121; RC121; P-Cttlvc-T; IM 4-28;
IUPAC/Chemical Name
(4R,7S,10R,13R,16R,19R)-13-((1H-indol-3-yl)methyl)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
InChi Key
MIUXMABDESTPBG-UHFFFAOYSA-N
InChi Code
1S/C50H67N11O10S2/c1-27(2)41-50(71)59-40(49(70)61-42(28(3)62)43(53)64)26-73-72-25-39(58-44(65)34(52)21-29-11-5-4-6-12-29)48(69)56-37(22-30-16-18-32(63)19-17-30)46(67)57-38(23-31-24-54-35-14-8-7-13-33(31)35)47(68)55-36(45(66)60-41)15-9-10-20-51/h4-8,11-14,16-19,24,27-28,34,36-42,54,62-63H,9-10,15,20-23,25-26,51-52H2,1-3H3,(H2,53,64)(H,55,68)(H,56,69)(H,57,67)(H,58,65)(H,59,71)(H,60,66)(H,61,70)
SMILES Code
O=C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)CSSC[C@H](NC([C@H](N)Cc1ccccc1)=O)C(N[C@H](Cc2ccc(O)cc2)C(N3)=O)=O)=O)C(C)C)[C@@H](CCCCN)NC([C@H]3Cc4c5ccccc5[nH]c4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,046.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Karashima T, Cai RZ, Schally AV. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sci. 1987 Aug 24;41(8):1011-9. Erratum in: Life Sci 1987 Sep 28;41(13):1665. PubMed PMID: 2886886. 2: László F, Pávó I, Penke B, Bálint GA. Protective effect of an orally administered, highly potent somatostatin analog (RC-121) against absolute ethanol-induced hemorrhagic erosions of the rat gastric mucosa. Life Sci. 1989;44(21):1573-8. PubMed PMID: 2733541. 3: Schally AV, Redding TW. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7275-9. PubMed PMID: 2890164; PubMed Central PMCID: PMC299275. 4: Banks WA, Schally AV, Barrera CM, Fasold MB, Durham DA, Csernus VJ, Groot K, Kastin AJ. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6762-6. PubMed PMID: 1975697; PubMed Central PMCID: PMC54617. 5: Radulovic S, Nagy A, Szoke B, Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett. 1992 Mar 15;62(3):263-71. PubMed PMID: 1317746. 6: Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res. 2000 Feb;6(2):709-17. PubMed PMID: 10690557. 7: Treszl A, Schally AV, Seitz S, Szalontay L, Rick FG, Szepeshazi K, Halmos G. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides. 2009 Sep;30(9):1643-50. doi: 10.1016/j.peptides.2009.06.007. Epub 2009 Jun 12. PubMed PMID: 19524629. 8: Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res. 1998 Sep 15;58(18):4132-7. PubMed PMID: 9751625. 9: Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J Urol. 2004 Feb;171(2 Pt 1):911-5. PubMed PMID: 14713852. 10: Halmos G, Schally AV, Comaru-Schally AM, Nagy A, Irimpen A. Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium. Life Sci. 2003 Apr 25;72(23):2669-74. PubMed PMID: 12672512. 11: Zalatnai A, Paz-Bouza JI, Redding TW, Schally AV. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Prostate. 1988;12(1):85-98. PubMed PMID: 2894651. 12: Keller G, Schally AV, Nagy A, Baker B, Halmos G, Engel JB. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. Int J Oncol. 2006 Jun;28(6):1507-13. PubMed PMID: 16685451. 13: Plonowski A, Schally AV, Nagy A, Sun B, Halmos G. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol. 2002 Feb;20(2):397-402. PubMed PMID: 11788908. 14: Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A. 1989 Mar;86(6):2003-7. PubMed PMID: 2564678; PubMed Central PMCID: PMC286834. 15: Redding TW, Schally AV. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers. Prog Clin Biol Res. 1988;262:217-40. PubMed PMID: 2897695. 16: Ikeda SR, Schofield GG. Somatostatin cyclic octapeptide analogs which preferentially bind to SOMa receptors block a calcium current in rat superior cervical ganglion neurons. Neurosci Lett. 1989 Jan 30;96(3):283-8. PubMed PMID: 2566139.